ClinicalTrials.gg

Program

Ciliary Neurotrophic Factor

Also written as “NT-501”, “Ciliary neurotrophic factor (CNTF)” and “NT-501/revakinagene taroretcel-lwey”.

Its studies are mostly in Telangiectasis · Retinitis Pigmentosa · Eye Diseases · Usher Syndromes, led by Neurotech Pharmaceuticals.

Furthest: phase 4, since Apr 29, 202511 company-led studies, 1 open or runningNext primary completion: Jan 15, 2032 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurotech Pharmaceuticals111 open or runningphase 4since Apr 29, 2025Mar 9, 2007Jan 15, 2032phase 4 · NCT06971939

Also a collaborator on its studies: the-emmes-company-llc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2007First studies: 3 phase 2 studiesFirst studyNCT00447993, NCT00447980, NCT00447954
  2. Mar 30, 2011Phase 1 study in Idiopathic Juxtafoveal Retinal TelangiectasiaNCT01327911 · 7 enrolled · United States
  3. Jan 19, 2012Phase 2 study in Retinitis PigmentosaNCT01530659 · 22 enrolled · United States
  4. Sep 19, 2013Phase 2 study in Macular Telangiectasia Type 2NCT01949324 · 67 enrolled · United States, Australia
  5. Mar 1, 2017Phase 2 study in MacTel (Macular Telangiectasia) Type 2NCT03071965 · 70 enrolled · United States, Australia
  6. Oct 3, 20172 phase 3 studiesNCT03319849, NCT03316300
  7. Jan 25, 2021Phase 2 study in Macular Telangiectasia Type 2NCT04729972 · 33 enrolled · United States, Australia
  8. Apr 29, 2025Phase 4 study in Macular Telangiectasia Type 2 (MacTel)NCT06971939 · 234 planned · United States, Australia

Ahead

  1. Jan 15, 2032Primary completion: phase 4 study in Macular Telangiectasia Type 2 (MacTel)NCT06971939

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06971939Macular Telangiectasia Type 2 (MacTel) · United States, Australia4RecruitingJan 15, 2032234
NCT04729972Macular Telangiectasia Type 2 · United States, Australia2CompletedDec 8, 202233
NCT03319849Macular Telangiectasia Type 2 · United States, Australia, Germany3CompletedAug 31, 2022119
NCT03316300Macular Telangiectasia Type 2 (MacTel) · United States, Australia, France and more3CompletedAug 31, 2022120
NCT03071965MacTel (Macular Telangiectasia) Type 2 · United States, Australia2CompletedMay 11, 202170
NCT01949324Macular Telangiectasia Type 2 · United States, Australia2CompletedApr 14, 201767
NCT01530659Retinitis Pigmentosa · United States2CompletedJul 1, 201922
NCT01327911Idiopathic Juxtafoveal Retinal Telangiectasia · United States1CompletedSep 20167
NCT00447993Retinitis Pigmentosa · United States2CompletedMay 26, 200967
NCT00447980Retinitis Pigmentosa · United States2CompletedApr 19, 201073
NCT00447954Eye Diseases · United States2CompletedMay 11, 200953

How it is read

Names in the registry

  • “NT-501”, 5 entries
  • “Ciliary neurotrophic factor (CNTF)”, 2 entries
  • “NT-501/revakinagene taroretcel-lwey”, 1 entry
  • “High Dose NT-501 implant”, 1 entry
  • “Low Dose NT-501 implant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.